HUMACYTE ($HUMA) posted quarterly earnings results for Q3 2026 on Tuesday, November 10th. The company reported earnings of -$0.07 per share, beating estimates of -$0.09 by $0.02. The company also reported revenue of $1,030,000, beating estimates of $781,320 by $248,680.
You can see Quiver Quantitative's $HUMA stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
HUMACYTE Insider Trading Activity
HUMACYTE insiders have traded $HUMA stock on the open market 7 times in the past 6 months. Of those trades, 5 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $HUMA stock by insiders over the last 6 months:
- KATHLEEN SEBELIUS purchased 56,818 shares for an estimated $49,999
- DALE A. SANDER (CFO and Chief Corp. Dev. Off) sold 45,887 shares for an estimated $41,146
- SHAMIK J PARIKH (Chief Medical Officer) sold 45,887 shares for an estimated $41,146
- KEITH ANTHONY JONES has made 3 purchases buying 50,000 shares for an estimated $30,370 and 0 sales.
- MICHAEL T. CONSTANTINO purchased 11,000 shares for an estimated $9,839
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
HUMACYTE Hedge Fund Activity
We have seen 76 institutional investors add shares of HUMACYTE stock to their portfolio, and 82 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BLACKROCK, INC. removed 7,477,026 shares (-60.7%) from their portfolio in Q2 2026, for an estimated $5,835,071
- ALYESKA INVESTMENT GROUP, L.P. added 6,022,925 shares (+inf%) to their portfolio in Q2 2026, for an estimated $4,700,290
- GREAT POINT PARTNERS LLC added 3,750,000 shares (+inf%) to their portfolio in Q2 2026, for an estimated $2,926,500
- ANTIPODES PARTNERS LTD removed 1,845,297 shares (-18.3%) from their portfolio in Q3 2026, for an estimated $955,310
- MILLENNIUM MANAGEMENT LLC added 1,800,895 shares (+1665.1%) to their portfolio in Q2 2026, for an estimated $1,405,418
- WOODLINE PARTNERS LP removed 1,502,000 shares (-75.0%) from their portfolio in Q2 2026, for an estimated $1,172,160
- SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 1,353,515 shares (+inf%) to their portfolio in Q2 2026, for an estimated $1,056,283
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
HUMACYTE Price Targets
Multiple analysts have issued price targets for $HUMA recently. We have seen 4 analysts offer price targets for $HUMA in the last 6 months, with a median target of $2.0.
Here are some recent targets:
- Joshua Jennings from TD Cowen set a target price of $1.25 on 06/17/2026
- Ryan Zimmerman from BTIG set a target price of $2.0 on 06/16/2026
- Swayampakula Ramakanth from HC Wainwright & Co. set a target price of $4.0 on 06/11/2026
- Bruce D. Jackson from Benchmark set a target price of $2.0 on 06/01/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.
